THR 687

Drug Profile

THR 687

Alternative Names: THR-687

Latest Information Update: 30 Mar 2016

Price : $50

At a glance

  • Originator Galapagos NV
  • Developer ThromboGenics
  • Class
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic retinopathy

Most Recent Events

  • 16 Mar 2017 ThromboGenics plans a phase I/II trial for Diabetic retinopathy around the end of 2017
  • 30 Mar 2016 Preclinical trials in Diabetic retinopathy in Belgium (Ophthalmic) (ThromboGenics' pipeline, March 2016)
  • 17 Mar 2016 ThromboGenics in-licenses THR 687 from Galapagos
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top